- Home
- JAZZ vs FDS Comparison
JAZZ vs FDS Comparison
Compare JAZZ & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | FDS |
|---|---|---|
| Founded | 2003 | 1978 |
| Country | Ireland | United States |
| Employees | N/A | 6258 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.0B |
| IPO Year | 2007 | 1996 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | FDS |
|---|---|---|
| Price | $189.20 | $214.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | $211.25 | ★ $300.10 |
| AVG Volume (30 Days) | 920.6K | ★ 1.3M |
| Earning Date | 05-15-2026 | 03-18-2026 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | N/A | ★ 11.79 |
| EPS | N/A | ★ 4.06 |
| Revenue | ★ $1,618,693,000.00 | $1,435,351,000.00 |
| Revenue This Year | $7.60 | $6.56 |
| Revenue Next Year | $8.34 | $5.30 |
| P/E Ratio | ★ N/A | $50.89 |
| Revenue Growth | N/A | ★ 6.31 |
| 52 Week Low | $95.49 | $185.00 |
| 52 Week High | $197.47 | $473.33 |
Technical Indicators
Market Signals| Indicator | JAZZ | FDS |
|---|---|---|
| Relative Strength Index (RSI) | 70.66 | 44.31 |
| Support Level | $159.78 | $185.00 |
| Resistance Level | N/A | $301.18 |
| Average True Range (ATR) | 5.04 | 10.83 |
| MACD | 2.69 | 3.08 |
| Stochastic Oscillator | 75.97 | 95.17 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.